Clinical Trial

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 12 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2023-08-13; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-03-03
Trial Details
NCT Number NCT05999240
Lead Sponsor New York State Psychiatric Institute
Collaborators: ACADIA Pharmaceuticals Inc., University of Kansas Medical Center, Research Foundation for Mental Hygiene, Inc., Weill Medical College of Cornell University
Conditions Autism Spectrum Disorder
Enrollment 30 participants
Start Date 2025-10-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01